NIW获批案例分享：病理学研究杰出人才
微信:hkmydym 来源:www.niw.cc 作者:www.niw.cc
Pursuant to 8 CFR §204.5(k)(2), Ms. Yang is an advanced degree professional by virtue of her Master of Science degree in Basic Discipline of Chinese and Western Integrative Medicine from Guangzhou University of Chinese Medicine (US equivalent to a Master of Science degree in Biomedical Sciences).
MS. YANG QUALIFIES FOR A NATIONAL INTEREST WAIVER
In the course of her work, Ms. Yang has acquired a formidable repertoire of knowledge and skills based on her accomplishments in the field of Bioinformatics and Medicine, particularly as it relates to pathology, diagnosing cancer and other rare diseases, and developing new drugs. She has conducted important scientific work in this field which have been funded by government agencies. There have been articles published about her and her work in professional and major media. She has played a leading and critical role in distinguished organizations. Due to her renowned reputation in the field, she has served as an expert in various capacities. Further details of her accomplishments and achievements in the field which evidence that she is well positioned to advance the proposed endeavor are provided below.
Ms. Yang’s Proposed Endeavor has both Substantial Merit and National Importance.
Ms. Yang endeavors are of both substantial merit and national importance, as described below:
1. Ms. Yang’s proposed endeavor is of substantial merit: Ms. Yang’s efforts in Bioinformatics and Medicine involve precision pathological diagnosis by using AI tools and models along with research into the development of new drugs and drug treatments. Therefore, such work is clearly of substantial merit.
2. Ms. Yang’s proposed endeavor is of national importance: Ms. Yang’s research and its applications have significant national and international implications and prospective impact for the field of Bioinformatics and Medicine and the United States. For example, according to the American Cancer Society, a little over 1.9 million new cancer cases are expected to be diagnosed in the US in 2023. Approximately 609,820 deaths from cancer are expected in the US in 2023, which is about 1,670 deaths per day. Cancer is the second most common cause of death in the US, exceeded only by heart disease. Moreover, in the United States, a disease is considered rare if it is affects fewer than 200,000 Americans. According to the National Institutes of Health (NIH), there are approximately 7,000 rare diseases affecting between 25 and 30 million Americans. This equates to 1 in 10 Americans. Of the 7,000 known rare diseases, approximately 95 percent have no treatment. Many rare diseases and disorders are not being studied by medical researchers. Often, patients are treated “off-label” (treatments that are not approved by the FDA for the specific disease), which can lead to insurance reimbursement problems.
MS. YANG QUALIFIES FOR A NATIONAL INTEREST WAIVER
In the course of her work, Ms. Yang has acquired a formidable repertoire of knowledge and skills based on her accomplishments in the field of Bioinformatics and Medicine, particularly as it relates to pathology, diagnosing cancer and other rare diseases, and developing new drugs. She has conducted important scientific work in this field which have been funded by government agencies. There have been articles published about her and her work in professional and major media. She has played a leading and critical role in distinguished organizations. Due to her renowned reputation in the field, she has served as an expert in various capacities. Further details of her accomplishments and achievements in the field which evidence that she is well positioned to advance the proposed endeavor are provided below.
Ms. Yang’s Proposed Endeavor has both Substantial Merit and National Importance.
Ms. Yang endeavors are of both substantial merit and national importance, as described below:
1. Ms. Yang’s proposed endeavor is of substantial merit: Ms. Yang’s efforts in Bioinformatics and Medicine involve precision pathological diagnosis by using AI tools and models along with research into the development of new drugs and drug treatments. Therefore, such work is clearly of substantial merit.
2. Ms. Yang’s proposed endeavor is of national importance: Ms. Yang’s research and its applications have significant national and international implications and prospective impact for the field of Bioinformatics and Medicine and the United States. For example, according to the American Cancer Society, a little over 1.9 million new cancer cases are expected to be diagnosed in the US in 2023. Approximately 609,820 deaths from cancer are expected in the US in 2023, which is about 1,670 deaths per day. Cancer is the second most common cause of death in the US, exceeded only by heart disease. Moreover, in the United States, a disease is considered rare if it is affects fewer than 200,000 Americans. According to the National Institutes of Health (NIH), there are approximately 7,000 rare diseases affecting between 25 and 30 million Americans. This equates to 1 in 10 Americans. Of the 7,000 known rare diseases, approximately 95 percent have no treatment. Many rare diseases and disorders are not being studied by medical researchers. Often, patients are treated “off-label” (treatments that are not approved by the FDA for the specific disease), which can lead to insurance reimbursement problems.
知识库